cefitinibtwo tablets dailylp消炎药

来源：蜘蛛抓取(WebSpider) 时间：2017-05-21 17:50 标签： febuxostat tablets
百度拇指医生
&&&普通咨询
您的网络环境存在异常，
请输入验证码
验证码输入错误，请重新输入百度拇指医生
&&&普通咨询
您的网络环境存在异常，
请输入验证码
验证码输入错误，请重新输入28/05/2017
IRESSA (gefitinib) as a first-line treatment for EGFR mutation-positive advanced NSCLC
IRESSA is an oral monotherapy treatment which offers superior progression-free survival, better tolerability and quality of life compared with doublet chemotherapy (carboplatin/paclitaxel) as first-line treatment for EGFR mutation-positive advanced NSCLC.
The IPASS study
IPASS (IRESSA Pan-ASia Study) was an open label, randomised, parallel-group study that assessed the efficacy, safety and tolerability of IRESSA versus doublet chemotherapy (carboplatin/paclitaxel) as 1st line treatment in a clinically selected population of patients from Asia.
Identifying EGFR mutation positive patients
Epidermal growth factor receptor (EGFR) is a protein found in abnormally high levels on the surface of many types of cancer cells, particularly non-small cell lung cancer (NSCLC) cells. A patient‘s EGFR mutation status (positive or negative) can be confirmed via a diagnostic test using a sample of tumour tissue.

我要回帖

更多关于 febuxostat tablets 的文章

 

随机推荐